Cell Therapy Products Draft Guidance on Pharmaceutical Change Evaluation Released by China NMPA

On July 1, 2025, China’s National Medical Products Administration (NMPA) released a draft guidance titled Technical Guiding Principles for Pharmaceutical Change Research and Evaluation of Cell Therapy Drugs (draft comment). Issued by the Center for Drug Evaluation (CDE), the document proposes a structured, risk-based framework for managing pharmaceutical changes across the lifecycle of cell therapy products. Draft comment was ended on August 1.

The guidance introduces a three-tier classification system for changes, outlines technical requirements for comparability studies, and recommends the use of quality risk assessment tools. It also addresses regulatory considerations specific to cell therapy, including the challenges posed by individualized manufacturing and variability in starting materials. International developers engaged in cell and gene therapy (CGT) should assess the implications of this draft for change control and regulatory compliance when operating in the China market.

Regulatory Context and Strategic Objectives

Cell therapy products, often referred to as “living drugs,” differ fundamentally from traditional chemical and biological drugs. Their high degree of personalization, complex manufacturing processes, and evolving understanding of quality attributes and clinical efficacy make conventional change management models insufficient.

Autologous CAR-T therapies, for example, rely on patient-derived cells that exhibit inherent biological variability. Changes such as viral vector process optimization, manufacturing site transfers, or adjustments to culture media can significantly impact product safety, efficacy and consistency.

With the rapid expansion of CGT clinical trials in China, the pace of technological innovation has outstripped existing regulatory frameworks. Developers frequently encounter change demands from early development through commercialization, such as plasmid vector optimization or closed-system transitions, without standardized evaluation criteria, risking delays or supply disruptions.

The draft guidance aims to establish a lifecycle-based change management system with two objectives:

Scientific Standardization: Define pharmaceutical change research strategies tailored to the unique characteristics of cell therapy products, avoiding a “one-size-fits-all” approach.
Innovation Enablement: Support the adoption of advanced technologies, such as automated closed systems and continuous-flow manufacturing to enhance scalability and robustness.

Scope of Application and Change Classification System

Product Scope
The guidance applies to cell therapy products derived from autologous or allogeneic human cells, including CAR-T cells, tumor-infiltrating lymphocytes (TILs), stem cells, islet cells, and chondrocytes. It excludes:

Blood components for transfusion
Germ cells
Hematopoietic stem cell transplantation without in vitro manipulation
Tissue and organ products composed of cells

Combination products involving cellular and non-cellular components may reference this guidance for the cellular portion.

Three-tier Change Classification

Major Changes: Likely to impact product quality, safety, or efficacy (e.g., viral vector production site changes, key raw material substitutions, analytical method shifts).
Moderate Changes: Changes with controlled risk, such as mirrored production line expansions under the same QA/QC system.
Minor Changes: Low-risk adjustments, such as seed bank additions or shelf-life extensions with validated stability data.

An annex provides detailed examples to guide classification decisions.

Key Technical Requirements for Change Evaluation

Risk Assessment and Lifecycle Planning
The guidance emphasizes the “Quality by Design” (QbD) concept, encouraging early integration of change management into R&D planning.

Early Planning: Major changes should be completed before confirmatory clinical trials to avoid data inapplicability due to process shifts.
Risk Control Tools: Use structured tools such as Failure Mode and Effects Analysis (FMEA) to assess the impact of changes on Critical Quality Attributes (CQAs), prioritizing high-risk areas like viral vector purity, cell viability.

Comparability Study Technical Requirements
The central principle is that changes must not adversely affect product quality, safety, or efficacy. The guidance proposes a multi-dimensional evidence framework:

Head-to-Head Comparisons: For autologous products, a split-based approach using the same donor cells before and after the change is recommended to minimize variability.
Statistical Methods: Techniques such as paired difference testing, equivalence analysis, and Quality Range evaluation are advised to support comparability conclusions.
Bridging Studies: Where comparability cannot be confirmed through pharmaceutical data alone, non-clinical and/or clinical bridging studies may be required.

Stability and Analytical Methodology

Stability Studies: Long-term, accelerated, and worst-case transport condition studies are required to assess the impact of changes on product shelf life.
Analytical Methods: New or optimized methods may be needed to detect changes in CQAs. Method transfer and equivalence testing are required when analytical sites or platforms change.

Innovation Support and Global Harmonization

Advanced Technologies: Adoption of closed automated systems, continuous-flow processes and in-line monitoring tools.
Alternative Analytical Methods: Use of novel techniques such as single-cell sequencing, AI-based quality control, provided they are scientifically justified.
Global Alignment: References international standards including ICH Q5E, FDA’s 2023 CGT guidance, and EMA ATMP Q&A framework.

Strategic Implications for CGT Developers

For both domestic and international CGT enterprises, establishing a robust, lifecycle-based change management system is essential, not only for regulatory compliance but also for ensuring product consistency, minimizing risk, and accelerating commercialization.

Early engagement with regulators, rigorous comparability planning, and proactive risk assessment will be key to navigating China’s evolving regulatory landscape for cell therapy products.

Further Information

To access the official draft of the Technical Guiding Principles for Pharmaceutical Change Research and Evaluation of Cell Therapy Products, released by China’s Center for Drug Evaluation (CDE), please click here.

For CGT developers and manufacturers seeking to align their change control strategies with China’s evolving regulatory expectations, our team at Cisema is available to provide strategic guidance and operational support. Please reach out to us to discuss how we can help you navigate this draft framework and ensure regulatory readiness.